Proteomics International Laboratories (ASX:PIQ) launched its PromarkerD blood test at the 85th Scientific Sessions of the American Diabetes Association in Illinois, according to a Friday filing with the Australian bourse.
The diagnostic tool is designed to predict the onset of diabetic kidney disease up to four years in advance in individuals with type 2 diabetes, the filing said.
The test, initially available in California, will be provided by the company's Clinical Laboratory Improvement Amendment-certified reference laboratory, per the filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。